Sarcoma

Sarcoma / 2019 / Article

Corrigendum | Open Access

Volume 2019 |Article ID 7608743 | 1 page | https://doi.org/10.1155/2019/7608743

Corrigendum to “SARC018_SPORE02: Phase II Study of Mocetinostat Administered with Gemcitabine for Patients with Metastatic Leiomyosarcoma with Progression or Relapse following Prior Treatment with Gemcitabine-Containing Therapy”

Received10 Jul 2019
Accepted15 Jul 2019
Published27 Aug 2019

In the article titled “SARC018_SPORE02: Phase II Study of Mocetinostat Administered with Gemcitabine for Patients with Metastatic Leiomyosarcoma with Progression or Relapse following Prior Treatment with Gemcitabine-Containing Therapy” [1], the second author, Dr. Ballman, was paid by Lilly and only recently realized that gemcitabine is a Lilly product and apologizes for not declaring this sooner.

References

  1. E. Choy, K. Ballman, J. Chen et al., “SARC018_SPORE02: phase II study of mocetinostat administered with gemcitabine for patients with metastatic leiomyosarcoma with progression or relapse following prior treatment with gemcitabine-containing therapy,” Sarcoma, vol. 2018, Article ID 2068517, 9 pages, 2018. View at: Publisher Site | Google Scholar

Copyright © 2019 Edwin Choy et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

637 Views | 172 Downloads | 0 Citations
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.